RxDoctor Payments Data

Richard Hall, MD

Medical Oncology · Charlottesville, VANPI 1649474040

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,721 of the $29,270 with a category attached, or 84.5%. 10 manufacturers reported payments, led by Regeneron at 29.2% of the total. Reporting peaked in 2024 at $15,455 and has fallen 68.3% since, to $4,897 in 2025.

$29,270in general payments, 2019–2025

Across 38 payments — averaging $770.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$9K
  • AstraZeneca$7K
  • AbbVie$3K
  • EMD Serono, Inc.$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Jazz Pharmaceuticals Inc.$2K
  • plus $3K from 4 others
$1,712,648in research payments, 2019–2025

Across 213 payments — averaging $8040.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$586K
  • Amgen$485K
  • Regeneron$439K
  • Merck$132K
  • AstraZeneca$29K
  • Mirati Therapeutics, Inc.$19K
  • plus $23K from 3 others

What the payments were for

  • Consulting fees$24,72184%
  • Travel & lodging$3,18511%
  • Food & beverage$1,3645%

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,270 in reported general payments places this provider in the 80th percentile of 95 medical oncology providers in Virginia.

See all medical oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$71,276
Medicare patients
164
Services billed
880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate42$649,052
LorbrenaLorlatinib16$342,048
EliquisApixaban38$27,412
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,019
Breo ElliptaFluticasone/Vilanterol13$5,329
Ondansetron Hcl44$994
Hydrocortisone28$676
Dexamethasone43$647
Albuterol Sulfate HfaAlbuterol Sulfate20$530
Olanzapine39$494
Levothyroxine Sodium33$426
Prochlorperazine Maleate33$418
Oxycodone Hcl25$367
Potassium Chloride13$173
Prednisone33$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$7,498$649,05242 claims
PfizerLorbrena, Eliquis$186$369,46054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 95 medical oncology providers in Virginia.

Other medical oncology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →